Komori
Intertrade (3747) · RiskMitigated

Share-Value Dilution from the Exercise of Stock Acquisition Rights

First written in FY2016. 14 of 20 entries say "Restated". Latest entry: FY2023.

20entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20192016: 12017: 220172018: 420182019: 420192020: 320202021: 220212022: 120222023: 32023
Same theme, other companies
Share Dilution from the Exercise of Stock OptionsA theme 405 companies write about · 406 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2017: 40 of 73 companies on the "Worse" side.

55 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 406 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2023MitigatedAnnual report

    「All of the relevant share acquisition rights expired because the exercise conditions were not met between the end of the fiscal year and the end of the month preceding the filing date (30 November 2023).」

    The share acquisition rights subject to performance conditions did not meet the exercise conditions and all expired by the end of the month preceding the filing date, eliminating the dilution exposure from potential shares.
  2. FY2023-Q3RestatedAnnual report

    「① Details of the stock option plan There are no applicable matters. ② Status of other stock acquisition rights, etc. There are no applicable matters.」

    The statement that there were no applicable items concerning the stock option plan or other share acquisition rights continues, with no new change in dilution exposure from potential shares indicated.
  3. FY2023-Q2MitigatedAnnual report

    「① Details of the stock option plan There are no applicable matters. ② Status of other stock acquisition rights, etc. There are no applicable matters.」

    The current quarterly report states that there were no applicable items concerning the stock option plan or other share acquisition rights, reducing the previously disclosed dilution exposure from potential shares.
  4. FY2022-Q3RestatedAnnual report

    「Overview of potential shares excluded from the calculation of quarterly net income per share after dilution because they had no dilutive effect and had undergone material changes since the end of the previous consolidated fiscal year - One type of share acquisition right 2,474 units (Share-based compensation subject to performance conditions)」

    The disclosure of 2,474 share acquisition rights in the form of share-based compensation subject to performance conditions continues to indicate the potential for dilution from potential shares. quantified=true, materialized=false.
  5. FY2021WorsenedAnnual report

    「As of the date of filing, the number of potential shares was 247,400, equivalent to 3.32% of the total number of issued shares, and the value of the shares could be diluted if the rights are exercised.」

    From a position in which no potential shares existed at the end of the previous fiscal year, the issuance of performance-linked paid stock options resulted in 247,400 potential shares, equivalent to 3.32% of total issued shares, making the dilution risk concrete again.
  6. FY2021-Q3RestatedAnnual report

    「During the third quarter of the consolidated cumulative period, there were no new business or other risks and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」

    It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights.
  7. FY2020MitigatedAnnual report

    「The company has introduced a stock option plan for directors, employees and external collaborators to encourage their willingness to contribute to the company and foster participation in management with an emphasis on shareholders, but as of 30 September 2020, no potential shares existed.」

    The 220,000 shares underlying the fifth series of share acquisition rights lapsed because the rights became uncertain, and it was explicitly stated that no potential shares existed as of the end of September 2020, reducing the dilution exposure.
  8. FY2020-Q3RestatedAnnual report

    「During the third quarter of the consolidated cumulative period, there were no significant changes in the financial position, operating results or cash flows. There were also no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」

    It states that there has been no material change regarding the risk of dilution of equity value from the exercise of stock acquisition rights.
  9. FY2020-Q1MitigatedAnnual report

    「Expiry of the fifth series of share acquisition rights (expiry date: 20 December 2019; number of share acquisition rights: 2,200)」

    The fifth series of share acquisition rights expired, and it was disclosed that no potential shares existed in the first quarter under review, reducing the dilution exposure from stock options and other instruments.
  10. FY2019RestatedAnnual report

    「The company has introduced a stock option plan for directors, employees and external collaborators to encourage their willingness to contribute to the company and foster participation in management with an emphasis on shareholders. As of 30 September 2019, potential shares existed. If stock options are granted and exercised in the future, the value of the shares could be further diluted. In addition, when new share acquisition rights are granted in the future, the difference between the issue price and market value may be recognized as an expense, which could affect the Group's business performance and other results.」

    The existence of potential shares, dilution from the exercise of stock options and the risk of expensing new grants continue to be disclosed.
  11. FY2019-Q3RestatedAnnual report

    「During the third quarter of the consolidated cumulative period, there were no significant changes in the financial position, operating results or cash flows. There were also no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」

    The company explains that there have been no material changes regarding the risk of dilution of share value from the exercise of share acquisition rights.
  12. FY2019-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」

    The company explains that there have been no material changes regarding the risk of dilution of share value from the exercise of share acquisition rights.
  13. FY2019-Q1RestatedAnnual report

    「During the first quarter of the consolidated cumulative period, there were no new business or other risks, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」

    The company explains that there have been no material changes regarding the risk of dilution of share value from the exercise of share acquisition rights.
  14. FY2018RestatedAnnual report

    「The company has introduced a stock option plan for directors, employees and external collaborators to encourage their willingness to contribute to the company and foster participation in management with an emphasis on shareholders. As of 30 September 2018, potential shares existed. If stock options are granted and exercised in the future, the value of the shares could be further diluted.」

    The existence of potential shares and the risk of dilution of share value from the exercise of stock options continue to be disclosed.
  15. FY2018-Q3RestatedAnnual report

    「There have been no material changes in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」

    The company explains that there have been no material changes regarding the risk of dilution of share value from the exercise of share acquisition rights.
  16. FY2018-Q2RestatedAnnual report

    「There have been no material changes in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」

    The company explains that there have been no material changes regarding the risk of dilution of share value from the exercise of share acquisition rights.
  17. FY2018-Q1RestatedAnnual report

    「There are no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    The company explains that there have been no material changes regarding the risk of dilution of share value from the exercise of share acquisition rights.
  18. FY2017RestatedAnnual report

    「If stock options are granted and exercised in the future, the value of the shares could be further diluted. In addition, when new share acquisition rights are granted in the future, the difference between the issue price and market value may be recognized as an expense, which could affect the Group's business performance and other results.」

    In addition to the risk of dilution from the exercise of share acquisition rights, the impact on business performance from expensing new grants is also disclosed.
  19. FY2017-Q3RestatedAnnual report

    「There have been no material changes in the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」

    The company explains that there have been no material changes regarding the risk of dilution of share value from the exercise of share acquisition rights.
  20. FY2016First statedAnnual report

    「The company has introduced a stock option plan for directors, employees and external collaborators to encourage their willingness to contribute to the company and foster participation in management with an emphasis on shareholders. As of 30 September 2016, potential shares existed. If stock options are granted and exercised in the future, the value of the shares could be further diluted.」

    The stock option plan is positioned as an incentive measure, and the possibility of dilution from the grant and exercise of potential shares is disclosed.
Moved together

"Healthcare business remains loss-making" moved the same way as this thread, in the same document, in 4 of its 20 moves.

443222★123456
  1. ★This thread
  2. 1Healthcare business remains loss-making4×
  3. 2Building a revenue base through expanded sales of GroupMAN@IT e²4×
  4. 3Expanding sales of Hanabiratake products, centered on the βeauty Glucan brand3×
  5. 4Concentration on the IT Hanabiratake business following the sale of the healthcare mail-order business2×
  6. 5Stable growth and transition to a renewed growth phase through a better-balanced business portfolio2×
  7. 6Business solutions business: dependence on spot projects, declining revenue and losses2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Intertrade's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.